Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00125138 · ClinicalTrials.gov registry record · Phase 2
Melperone (an Anti-Psychotic) in Patients With Psychosis Associated With Parkinson's Disease
A Phase 2 study, sponsored by Lundbeck.
- Completed
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
NCT00125138 is a Phase 2 study that has completed, run by Lundbeck. The registered enrollment target is 90 participants.
The verdict
NCT00125138, a Phase 2 study, has completed, sponsored by Lundbeck.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of three target doses of melperone compared to placebo in the treatment of psychosis associated with Parkinson's disease. Subjects will be enrolled at approximately 20 investigational sites in the United States (U.S.) and 15 Ex-US sites. The maximum study duration will be 10 weeks. Subjects will have the option of continuing in an open-label extension study.
Interventions
- DRUG Placebo
- DRUG Melperone HCl
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2005-07 |
| Est. Completion | 2008-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00125138
The ClinicalTrials.gov registry entry for NCT00125138 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lundbeck, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00125138 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00125138 about?
NCT00125138 is a clinical study titled "Melperone (an Anti-Psychotic) in Patients With Psychosis Associated With Parkinson's Disease". The purpose of this study is to evaluate the safety and efficacy of three target doses of melperone compared to placebo in the treatment of psychosis associated with Parkinson's disease. Subjects will be enrolled at approximately 20 investigational sites in the United States (U.S.) and 15 Ex-US site...
What is the current status of trial NCT00125138?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2005-07. Estimated completion is 2008-04.
What interventions are being tested in trial NCT00125138?
The interventions under investigation include: Placebo (DRUG), Melperone HCl (DRUG).
Who is sponsoring clinical trial NCT00125138?
This trial is sponsored by Lundbeck, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.